Keros Therapeutics Inc’s filing revealed that its 10% Owner ADAR1 Capital Management, LLC acquired Company’s shares for reported $9.46 million on Apr 09 ’25. In the deal valued at $10.13 per share,934,258 shares were bought. As a result of this transaction, ADAR1 Capital Management, LLC now holds 4,392,737 shares worth roughly $60.0 million.
Then, GORDON CARL L sold 250,000 shares, generating $11,002,500 in total proceeds. Upon selling the shares at $44.01, the Director now owns 119,522 shares.
Before that, ORBIMED ADVISORS LLC sold 250,000 shares. Keros Therapeutics Inc shares valued at $11,002,500 were divested by the Director at a price of $44.01 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 119,522 shares, worth roughly $1.63 million.
BofA Securities downgraded its Keros Therapeutics Inc [KROS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late January from “an Overweight” to “a Neutral”. Wedbush also remained covering KROS and has decreased its forecast on January 17, 2025 with a “Neutral” recommendation from previously “an Outperform” rating. Oppenheimer maintained its rating on December 16, 2024. It rated KROS as “an Outperform”.
Price Performance Review of KROS
On Monday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock jump 0.74% to $13.66. Over the last five days, the stock has lost -3.05%. Keros Therapeutics Inc shares have fallen nearly -13.71% since the year began. Nevertheless, the stocks have fallen -72.11% over the past one year. While a 52-week high of $72.37 was reached on 01/02/25, a 52-week low of $9.12 was recorded on 04/09/25.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 13.47, which if violated will result in even more drops to 13.28. On the upside, there is a resistance level at 13.88. A further resistance level may holdings at 14.10.
